High materiality8/10
H.C. Wainwright Reiterates Buy Rating on Insmed (INSM)
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
INSM received an analyst target update from H.C. Wainwright.
- Target raised to $220 by H.C. Wainwright.
Key facts
- 01
Target: $220
- 02
Posted price: $108.32
- 03
Analyst firm: H.C. Wainwright
- 04
Analyst: Andrew Fein
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.